RT Journal Article
SR Electronic
T1 Multimodal analysis of methylomics and fragmentomics in plasma cell-free DNA for multi-cancer early detection and localization
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.04.12.23288460
DO 10.1101/2023.04.12.23288460
A1 Nguyen, Van Thien Chi
A1 Nguyen, Trong Hieu
A1 Doan, Nhu Nhat Tan
A1 Pham, Thi Mong Quynh
A1 Nguyen, Giang Thi Huong
A1 Nguyen, Thanh Dat
A1 Tran, Thuy Thi Thu
A1 Vo, Duy Long
A1 Phan, Thanh Hai
A1 Jasmine, Thanh Xuan
A1 Nguyen, Van Chu
A1 Nguyen, Huu Thinh
A1 Nguyen, Trieu Vu
A1 Nguyen, Thi Hue Hanh
A1 Huynh, Le Anh Khoa
A1 Tran, Trung Hieu
A1 Dang, Quang Thong
A1 Doan, Thuy Nguyen
A1 Tran, Anh Minh
A1 Nguyen, Viet Hai
A1 Nguyen, Vu Tuan Anh
A1 Ho, Le Minh Quoc
A1 Tran, Quang Dat
A1 Pham, Thi Thu Thuy
A1 Ho, Tan Dat
A1 Nguyen, Bao Toan
A1 Nguyen, Thanh Nhan Vo
A1 Nguyen, Thanh Dang
A1 Phu, Dung Thai Bieu
A1 Phan, Boi Hoan Huu
A1 Vo, Thi Loan
A1 Nai, Thi Huong Thoang
A1 Tran, Thuy Trang
A1 Truong, My Hoang
A1 Tran, Ngan Chau
A1 Le, Trung Kien
A1 Tran, Thanh Huong Thi
A1 Duong, Minh Long
A1 Bach, Hoai Phuong Thi
A1 Kim, Van Vu
A1 Pham, The Anh
A1 Tran, Duc Huy
A1 Le, Trinh Ngoc An
A1 Pham, Truong Vinh Ngoc
A1 Le, Minh Triet
A1 Vo, Dac Ho
A1 Tran, Thi Minh Thu
A1 Nguyen, Minh Nguyen
A1 Van, Thi Tuong Vi
A1 Nguyen, Anh Nhu
A1 Tran, Thi Trang
A1 Tran, Vu Uyen
A1 Le, Minh Phong
A1 Do, Thi Thanh
A1 Phan, Thi Van
A1 Nguyen, Luu Hong Dang
A1 Nguyen, Duy Sinh
A1 Cao, Van Thinh
A1 Do, Thanh Thuy Thi
A1 Truong, Dinh Kiet
A1 Tang, Hung Sang
A1 Giang, Hoa
A1 Nguyen, Hoai Nghia
A1 Phan, Minh Duy
A1 Tran, Le Son
YR 2023
UL http://medrxiv.org/content/early/2023/08/01/2023.04.12.23288460.abstract
AB Despite their promise, circulating tumor DNA (ctDNA)-based assays for multi-cancer early detection face challenges in test performance, due mostly to the limited abundance of ctDNA and its inherent variability. To address these challenges, published assays to date demanded a very high-depth sequencing, resulting in an elevated price of test. Herein, we developed a multimodal assay called SPOT-MAS (Screening for the Presence Of Tumor by Methylation And Size) to simultaneously profile methylomics, fragmentomics, copy number, and end motifs in a single workflow using targeted and shallow genome-wide sequencing (∼0.55X) of cell-free DNA. We applied SPOT-MAS to 738 nonmetastatic patients with breast, colorectal, gastric, lung and liver cancer, and 1,550 healthy controls. We then employed machine learning to extract multiple cancer and tissue-specific signatures for detecting and locating cancer. SPOT-MAS successfully detected the five cancer types with a sensitivity of 72.4% at 97.0% specificity. The sensitivities for detecting early-stage cancers were 62.3% and 73.9% for stage I and II, respectively, increasing to 88.3% for nonmetastatic stage IIIA. For tumor-of-origin, our assay achieved an accuracy of 0.7. Our study demonstrates comparable performance to other ctDNA-based assays while requiring significantly lower sequencing depth, making it economically feasible for population-wide screening.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study was funded by Gene SolutionsAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Ethics Committee of the Medic Medical Center, University of Medicine and Pharmacy and Medical Genetics Institute, Ho Chi Minh city, Vietnam.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesSequencing data will be deposited in a public portal database (NCBI SRA) upon acceptance and are available on request from the corresponding author, LST. The data are not publicly available due to ethical restrictions.MCEDMulti-cancer early detectionTOOtissue of origincfDNACirculating cell-free DNActDNACirculating tumor DNASPOT-MASScreening for the Presence Of Tumor by DNA Methylation And SizeAUCArea Under the CurveTMTargeted methylationGWMGenome-wide methylationCNACopy number aberrationFLENFragment lengthEMEnd motifLBLiquid BiopsyLRLogistic regressionRFRandom ForestXGBExtreme Gradient BoostingDNNDeep neural networkGCNNGraph Convolutional Neural NetworkCRCColorectal cancerROCReceiver Operating Characteristic